Why is randomization in clinical trials important?

Article

I am no stranger to the importance of randomization when conducting a study. I minored in psychology as an undergraduate, so I took part in the experimentation process--both by being experimented on and running an experiment. And the process of running experiments, holding trials and conducting studies was repeated until well known, and I was even tested on it. I also had to conduct my own studies and experiments in graduate school. Even if I was just conducting a content analysis (a fairly basic research technique used to examine texts), I would still need randomization.So why am I giving you my research background? Because I've never thought about the research process without randomization. Because I've never thought about what randomization might mean to the average person. And because I read a thought-provoking obit in The New York Times about the man who helped institute randomization in clinical trials in our country. Paul Meier, who died Aug. 7 from complications related to a stroke, essentially revolutionized the way we run clinical trials. Before Meier, researchers would test a new drug or treatment on patients they thought would have the greatest benefit, and then they would compare the data to other patients who didn't receive the treatment. Now what's wrong with this you say? It seems like people who need the treatment are receiving it. But the problem with this setup is bias. The people receiving the treatment could be stronger, healthier than those not receiving the treatment. Or there could be more people from one ethnicity, gender or age than another. Therefore, the results couldn't be generalized to a larger population because you wouldn't really know who gets the most benefit. Randomization ensures that both samples, those receiving treatment and those who aren't, are similar. Not only does this mean that the researcher can then translate the results to a larger population, but the math and the science behind the study are stronger. Meaning you get better results.And Meier was the person who insisted on this process in the U.S. Today, the Food and Drug Administration requires randomized trials be conducted before they'll approve a drug. And young researchers like me learn about randomization as part of the scientific process. And while this might seem inconsequential or it causes delays in getting treatments to patients, it's better for patients in the long run because it means safer and more effective treatments that are right for them.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content